Omega-3 polyunsaturated fatty acids supplementation in patients with diabetes and cardiovascular disease risk: does dose really matter?

about

Omega-3 polyunsaturated fatty acids supplementation in patients with diabetes and cardiovascular disease risk: does dose really matter?

Item

http://www.wikidata.org/entity/Q58699954

description

im August 2018 veröffentlichter wissenschaftlicher Artikel

@de

scientific article published on 28 August 2018

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в серпні 2018

@uk

name

Omega-3 polyunsaturated fatty ...... risk: does dose really matter?

@en

Omega-3 polyunsaturated fatty ...... risk: does dose really matter?

@nl

type

Item

label

Omega-3 polyunsaturated fatty ...... risk: does dose really matter?

@en

Omega-3 polyunsaturated fatty ...... risk: does dose really matter?

@nl

prefLabel

Omega-3 polyunsaturated fatty ...... risk: does dose really matter?

@en

Omega-3 polyunsaturated fatty ...... risk: does dose really matter?

@nl

P1476

Omega-3 polyunsaturated fatty ...... risk: does dose really matter?

@en

P2093

Alexander Tenenbaum

http://www.w3.org/2001/XMLSchema#string

P2860

Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease

Treatment with high-dose n-3 PUFAs has no effect on platelet function, coagulation, metabolic status or inflammation in patients with atherosclerosis and type 2 diabetes.

Effect of n-3 Polyunsaturated Fatty Acid Supplementation on Metabolic and Inflammatory Biomarkers in Type 2 Diabetes Mellitus Patients

Omega-3 fatty acid supplementation and cardiovascular disease.

Fish oil -- how does it reduce plasma triglycerides?

Hepatic insulin resistance both in prediabetic and diabetic patients determines postprandial lipoprotein metabolism: from the CORDIOPREV study.

Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives.

Atherogenic dyslipidemia and risk of silent coronary artery disease in asymptomatic patients with type 2 diabetes: a cross-sectional study.

Effects of 6-month eicosapentaenoic acid treatment on postprandial hyperglycemia, hyperlipidemia, insulin secretion ability, and concomitant endothelial dysfunction among newly-diagnosed impaired glucose metabolism patients with coronary artery dise

Cholesterol remnants and triglycerides are associated with decreased myocardial function in patients with type 2 diabetes

P2888

s12933-018-0766-0

P304

119

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.1186/S12933-018-0766-0

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Enrique Z Fisman

P577

2018-08-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1106387016

http://www.w3.org/2001/XMLSchema#string

P698

30153832

http://www.w3.org/2001/XMLSchema#string

P921

cardiovascular disease

P932

6112138

http://www.w3.org/2001/XMLSchema#string